AMDL, Through Its Chinese Subsidiary JJB, Signs to Partner With a Medical Distribution Company in Order to Expand Sales in China
November 06 2006 - 8:00AM
PR Newswire (US)
TUSTIN, Calif., Nov. 6 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL), announced today that its wholly owned subsidiary
Jiangxi Jade Biochemistry, Ltd. (JJB) has executed a Memorandum of
Understanding (MOU) with Jiangxi Baikang Medicine Co., Ltd. (JMB)
for a distribution arrangement that it is anticipated will provide
significantly expanded product distribution in China for various
existing and to-be-developed JJB products. Both companies are
headquartered in Jiangxi Province. JMB, a Chinese pharmaceutical
company and drug distributor founded in 2004, has varied operations
in the distribution of ready-made Chinese medicines, chemicals and
medical raw materials, medical preparations, anti-biological
preparations, chemical medicines, biochemical medicines and
biological products. Both JJB and JMB entered into the MOU in order
to achieve a broader-based and more profitable business for both
parties. This cooperation is anticipated to include sales and
distribution agreements, manufacturing agreements, and licensing
agreements including the possible acquisition of JMB by JJB. As
part of the initial phase of the cooperation, the parties will
negotiate a mutually beneficial Product Licensing Agreement (PLA)
in which JMB agrees to transfer its four new drugs (including
Marine and Sodium Chloride Injection, Lomefloxacin Aspartate
Injection, Lysine Hydrochloride and Glucose Injection, Omeprazole
Sodium for Injection) and two generic medicine (including
Roxithromycin capsule and Levofloxacin capsule) production licenses
and manufacturing registration numbers to JJB. "This Partnership,
when completed, is expected to significantly expand JJB's product
offerings and their distribution reach within China. We are very
excited about this new business development partnership, and we
will work to finalize the key objectives noted in the MOU," said
Gary Dreher, AMDL CEO. About AMDL AMDL, Inc. (AMEX:ADL),
headquartered in Tustin, California, with operations in Shenzhen,
Jaingxi and Jilin China through its wholly owned subsidiary Jade
Pharmaceutical Inc. is an international biopharma company. AMDL
together with Jade engages in the development, manufacture and
marketing of proprietary pharmaceutical and testing products. More
information about AMDL and its additional products can be obtained
at http://www.amdl.com/ . Forward-Looking Statements This news
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such
statements are subject to certain risks and uncertainties, and
actual circumstances, events or results may differ materially from
those projected in such forward-looking statements. The Company
cautions readers not to place undue reliance on any forward-looking
statements. The Company does not undertake, and specifically
disclaims any obligation, to update or revise such statements to
reflect new circumstances or unanticipated events as they occur.
Contact: AMDL, Inc. Gary L. Dreher President & CEO (714)
505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President
& CEO of AMDL, Inc., +1-714-505-4460 Web site:
http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jul 2023 to Jul 2024